Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

NCT02783625 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT02783625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02783625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
May 23, 2016
Completion date
April 21, 2026
Enrollment
114 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, relapsed/refractory t-cell lymphomas